Supportive treatment is the main treatment strategy. There is no effective antiviral agent against SFTS. Patients require close monitoring of their respiratory condition and blood pressure. Adequate fluid administration, close monitoring and management of thrombocytopenia, haemophagocytic syndrome and secondary bacterial infection are important.

The case-fatality rate has been reported to range from 6.3% to 30% in China and be 23.2% in Japan. Older age, impaired consciousness and high serum LDH and CK levels are associated with high lethality.